A potential first-in-class active immunotherapy designed to delay or slow Alzheimer's disease progression may realize up to approximately $2.1 billion in new funding.
Takeda and AC Immune SA today announced an exclusive, worldwide option and license agreement for AC Immune's active immunotherapies, including ACI-24.060, which targets toxic forms of amyloid beta (Abeta).
Read More
